■ MATERIAL WEAKNESS WATCH
Nasdaq · CIK 0001005286

LFCR LIFECORE BIOMEDICAL, INC. DE

B
80 / 100
Material weaknesses
1
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
0
Deductions
20
Remediation credit
0

Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.

Disclosures, in the company's words

  • Material weakness10-Q · filed 2026-11-04 · Item 4source filing ↗
    “As disclosed in Item 9A of our Transition Report on Form 10-KT for the transition period ended December 31, 2025, management identified a material weakness related to the design and operation of controls within the information and communication and control activities components of the COSO framework, arising from limitations in our legacy ERP environment.”
  • Controls not effective10-Q · filed 2026-11-04 · Item 4source filing ↗
    “Based upon such evaluation, our principal executive officer and principal financial officer concluded that, because the material weakness in our internal control over financial reporting described in our Transition Report on Form 10-KT for the transition period ended December 31, 2025 had not been fully remediated as of September 30, 2026, our disclosure controls and procedures were not effective as of September 30, 2026.”

Filings read

Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.